T1	p 70 157	postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy
T2	p 450 550	Four hundred patients with stage II and III rectal cancer received postoperative CRT of capecitabine
T3	p 695 728	hundred and twenty-eight patients
T4	i 18 42	CCND1 A870G polymorphism
T5	i 120 159	adjuvant concurrent chemoradiotherapy ]
T6	i 241 279	single nucleotide polymorphism ( SNP )
T7	i 322 327	AEs )
T8	i 381 439	capecitabine-based postoperative chemoradiotherapy ( CRT )
T9	i 531 534	CRT
T10	i 567 578	oxaliplatin
T11	i 758 799	capecitabine and radiotherapy ( Cap-CRT )
T12	i 832 901	with capecitabine and oxaliplatin plus radiotherapy ( Cap-Oxa-CRT ) .
T13	i 946 964	Common Terminology
T14	i 995 1016	v. 3.0 ( CTCAE v3.0 )
T15	i 2603 2665	concurrent chemoradiotherapy of capecitabine and oxaliplatin .
T16	o 46 66	acute adverse events
T17	o 902 916	Adverse events
T18	o 978 992	Adverse Events
T19	o 1123 1164	fragment length polymorphism ( PCR-RFLP )
T20	o 1205 1222	SNP and acute AEs
T21	o 1471 1473	AA
T22	o 1606 1614	Diarrhea
T23	o 1644 1659	severe diarrhea
T24	o 1716 1740	genotypes GG , GA and AA
T25	o 1966 1990	risk for severe diarrhea
T26	o 2220 2244	risk for severe diarrhea
T27	o 2398 2415	severe diarrhea .